HER2 Amplification Detection by FISH at Chughtai Lab

Understanding HER2 Amplification Detection by FISH at Chughtai Lab

Human Epidermal Growth Factor Receptor 2 (HER2) is a proto-oncogene located on chromosome 17q21. It encodes a 185 kDa transmembrane tyrosine kinase receptor that plays a pivotal role in regulating cell growth, survival, and differentiation. In approximately 15% to 20% of invasive breast cancers, as well as a significant proportion of gastric and gastroesophageal junction adenocarcinomas, the HER2 gene is amplified. This amplification leads to the overexpression of the HER2 protein on the cell surface, driving aggressive tumor behavior, increased rates of recurrence, and poorer overall prognosis. Accurate determination of HER2 status is clinically critical, as it directly dictates patient eligibility for highly effective HER2-targeted therapies, such as trastuzumab, pertuzumab, and antibody-drug conjugates like trastuzumab deruxtecan.

Fluorescence In Situ Hybridization (FISH) is widely considered the gold-standard molecular cytogenetic methodology for evaluating HER2 gene status. Unlike immunohistochemistry (IHC), which measures protein expression on the cell membrane and can be subject to pre-analytical variations, FISH directly detects the number of copies of the HER2 gene DNA within the nuclei of tumor cells. By utilizing fluorescently labeled DNA probes that hybridize specifically to the HER2 gene locus and the centromere of chromosome 17 (CEP17), FISH provides a highly quantitative, objective, and reproducible assessment of gene amplification. At Chughtai Lab, this sophisticated molecular testing is performed within a specialized cytogenetics and molecular pathology facility, utilizing advanced fluorescence microscopy and automated hybridization systems to ensure the highest standards of diagnostic precision.

The clinical importance of HER2 Amplification Detection by FISH cannot be overstated. It serves as a definitive diagnostic tool, particularly in cases where IHC results are equivocal (IHC 2+). By precisely quantifying the ratio of HER2 gene copies to chromosome 17 centromeres, the assay helps oncologists distinguish between true gene amplification and chromosome 17 polysomy. This distinction is vital for avoiding both under-treatment of patients who would benefit from targeted therapy and over-treatment of those who would not, thereby optimizing therapeutic efficacy while minimizing unnecessary toxicity and healthcare costs.

Clinical Procedure: What to Expect

Patient Preparation

Because HER2 Amplification Detection by FISH is a specialized molecular test performed on tissue specimens rather than directly on the patient’s body, the preparation steps focus primarily on specimen collection, documentation, and preservation:

• No Direct Patient Fasting: Since the test is performed on an existing tissue block, patients do not need to fast or alter their daily medication schedules.
• Submission of Tissue Block and Slides: Patients or their clinical teams must submit the Formalin-Fixed Paraffin-Embedded (FFPE) tissue block along with the corresponding hematoxylin and eosin (H&E) stained histopathology slides and the original biopsy report.
• Specimen Fixation Requirements: For optimal results, the tissue must have been fixed in 10% neutral buffered formalin for a minimum of 6 hours and a maximum of 72 hours, in strict accordance with ASCO/CAP guidelines. Improper fixation can lead to DNA degradation and test failure.
• Clinical History Documentation: It is essential to provide complete clinical details, including the primary tumor site (e.g., breast, stomach), previous IHC HER2 results, and the patient’s treatment history.

During the Procedure

The laboratory workflow for FISH is highly technical and involves several precise steps executed by specialized molecular technologists:

• Tissue Selection: A consultant pathologist reviews the H&E slide to identify the areas of invasive carcinoma with the highest tumor cellularity, ensuring that benign tissues or necrotic areas are excluded from analysis.
• Sectioning and Deparaffinization: Ultra-thin sections (typically 4-5 micrometers) are cut from the FFPE block, mounted on positively charged glass slides, and subjected to chemical deparaffinization and rehydration.
• Pretreatment and Enzymatic Digestion: The tissue sections undergo heat-induced pretreatment and enzymatic digestion to break down protein cross-links, making the nuclear DNA accessible to the molecular probes.
• Probe Application and Denaturation: A mixture of dual-color fluorescent probes—typically an orange/red probe for the HER2 gene locus and a green probe for the CEP17 locus—is applied to the slide. The slide is then placed in an automated co-denaturation system to melt the double-stranded DNA of both the target and the probes.
• Hybridization: The slides are incubated at a controlled temperature (usually 37 degrees Celsius) for 14 to 18 hours, allowing the fluorescent probes to bind specifically to their complementary sequences on the patient’s DNA.
• Post-Hybridization Washing and Counterstaining: Unbound probes are washed away using stringent wash buffers. The cell nuclei are then counterstained with DAPI (a blue fluorescent dye) to visualize the nuclear boundaries.
• Fluorescence Microscopy and Signal Counting: A molecular pathologist examines the slides under a high-resolution fluorescence microscope equipped with specialized filters. The pathologist counts the orange (HER2) and green (CEP17) signals in at least 20 non-overlapping, contiguous invasive tumor cell nuclei to calculate the average HER2 copy number and the HER2/CEP17 ratio.

When is a HER2 Amplification Detection by FISH Performed?

Invasive Breast Carcinoma Diagnosis

Every patient newly diagnosed with invasive breast cancer must have their HER2 status determined. While immunohistochemistry (IHC) is often used as the initial screening tool, FISH is performed either as the primary diagnostic test or as a reflex test to confirm the presence or absence of gene amplification, ensuring accurate prognostic stratification from the outset.

Equivocal Immunohistochemistry (IHC 2+) Results

The most common clinical indication for HER2 FISH is an equivocal (2+) result on initial IHC testing. IHC 2+ indicates weak-to-moderate complete membrane staining in more than 10% of tumor cells. Because this result is borderline, clinical guidelines mandate reflex testing with FISH to definitively determine whether the underlying gene is amplified, thereby resolving diagnostic ambiguity.

Advanced or Metastatic Gastric Adenocarcinoma

In patients diagnosed with advanced, recurrent, or metastatic adenocarcinoma of the stomach or gastroesophageal junction, HER2 status must be evaluated. FISH testing is performed to identify patients who are candidates for first-line trastuzumab therapy combined with chemotherapy, which has been shown to significantly improve overall survival in HER2-positive gastric cancer cases.

Recurrent or Metastatic Breast Cancer

When breast cancer recurs or metastasizes, the biological characteristics of the tumor can change—a phenomenon known as receptor discordance. Physicians frequently order a biopsy of the metastatic lesion and request HER2 FISH testing to determine if the tumor has acquired HER2 amplification, which would open up new targeted therapeutic avenues.

Clarification of Discordant Clinical or Pathological Findings

In cases where the histopathological grade of the tumor does not align with the initial screening results, or when there is high intratumoral heterogeneity, clinicians request FISH. The high specificity of FISH allows pathologists to map gene amplification directly to specific tumor areas, resolving discrepancies and guiding precise clinical decision-making.

What Does a HER2 Amplification Detection by FISH Detect?

The HER2 Amplification Detection by FISH assay is designed to detect and quantify specific genetic and chromosomal alterations within tumor cell nuclei. The primary findings and parameters evaluated during this molecular analysis include:

• HER2 Gene Copy Number: The average number of HER2 gene signals per tumor cell nucleus.
• CEP17 Copy Number: The average number of chromosome 17 centromere signals per nucleus, which serves as an internal control.
• HER2/CEP17 Ratio: The mathematical ratio of total HER2 signals to total CEP17 signals across the evaluated cells.
• HER2 Gene Amplification: Defined by ASCO/CAP guidelines as a HER2/CEP17 ratio of 2.0 or greater, or an average HER2 copy number of 6.0 or more signals per cell.
• Non-Amplification of HER2: Defined as a HER2/CEP17 ratio of less than 2.0 and an average HER2 copy number of less than 4.0 signals per cell.
• Equivocal HER2 Status: Borderline cases that require additional cell counting or reflex testing.
• Polysomy of Chromosome 17: An increased number of CEP17 signals (typically an average of 3 or more per nucleus), indicating that the entire chromosome is duplicated rather than just the HER2 gene.
• Monosomy of Chromosome 17: A decrease in CEP17 signals (average of less than 1.5 per nucleus), indicating the loss of one copy of chromosome 17.
• Intratumoral Heterogeneity: The presence of distinct sub-populations of tumor cells, where some areas show gene amplification and others do not.
• Atypical Signal Patterns: Co-localized or clustered HER2 signals indicating high-level gene amplification.
• Nuclear Morphology: Assessment of nuclear size, shape, and integrity within the invasive tumor component.
• Technical Artifacts: Identification of background noise, non-specific binding, or tissue autofluorescence that could interfere with interpretation.
• Inadequate Tumor Cellularity: Detection of specimens with insufficient invasive tumor cells to perform a valid count.
• DNA Degradation: Assessment of whether the tissue’s DNA is intact enough to allow successful probe hybridization.

Turnaround Time and Report Access at Chughtai Lab

At Chughtai Lab, we understand that waiting for oncology test results can be an anxious time for patients and their families. Because FISH is a complex molecular technique requiring tissue processing, overnight hybridization, and expert analysis by a consultant pathologist, the turnaround time is typically 7 to 10 working days from the receipt of the specimen at the molecular pathology department.

Chughtai Lab offers seamless digital access to diagnostic reports. Once the consultant pathologist signs off on the final report, patients and their referring physicians receive an automated SMS notification. Reports can be viewed, downloaded, and printed directly from the official Chughtai Lab website or through the user-friendly Chughtai Lab Mobile App. Physical copies of the reports can also be collected from any of our extensive network of collection centers across Pakistan, or delivered directly to the patient’s home through our dedicated report delivery service.

HER2 Amplification Detection by FISH Findings Overview

Structure / Parameter Evaluated	Normal Findings	Possible Abnormal Findings
HER2/CEP17 Ratio	Ratio < 2.0 (typically around 1.0 to 1.3)	Ratio >= 2.0 (indicates gene amplification)
Average HER2 Copy Number	< 4.0 signals per nucleus	>= 6.0 signals per nucleus (amplified status)
Chromosome 17 Status (CEP17)	Normal diploid state (average of 1.5 to 2.4 signals per cell)	Polysomy (average >= 3.0 signals) or Monosomy (average < 1.5 signals)
Clinical Interpretation	HER2 Negative (not candidate for HER2-targeted therapy)	HER2 Positive (eligible for HER2-targeted therapies like Trastuzumab)
Tumor Cell Suitability	Abundant, viable invasive tumor cells with intact nuclei	Inadequate tumor cellularity, extensive necrosis, or benign tissue contamination
Signal Quality	Bright, distinct, and easily countable fluorescent signals	Faint signals, high background autofluorescence, or probe hybridization failure

Note: Diagnostic findings should always be interpreted by a qualified healthcare professional together with the patient’s symptoms, medical history, physical examination, laboratory investigations, previous imaging studies, and other relevant clinical information. Additional investigations or specialist consultation may be recommended depending on the findings.

Why Choose Chughtai Lab for HER2 Amplification Detection by FISH?

• Experienced Healthcare Professionals: Our molecular pathology department is led by highly qualified consultant pathologists and cytogeneticists with extensive experience in oncological diagnostics.
• Patient-Focused Care: We prioritize patient comfort, clear communication, and timely support throughout the diagnostic journey.
• Quality Diagnostic Services: Chughtai Lab adheres to stringent international quality control standards, ensuring highly reproducible and accurate FISH results.
• Professional Reporting: Our reports are detailed, structured according to international guidelines (ASCO/CAP), and designed to provide clear clinical utility for oncologists.
• Modern Diagnostic Approach: We utilize state-of-the-art fluorescence microscopes, high-precision hybridization chambers, and premium-quality FDA-approved probe kits.
• Comfortable Environment: Our collection centers and main diagnostic facilities are designed to provide a welcoming, professional, and stress-free experience.
• Convenient Location: With a vast network of collection centers across Pakistan, patients can easily submit their tissue blocks and slides close to home.
• Commitment to Accurate Diagnosis: We employ rigorous internal and external quality assurance programs to ensure that every molecular test result is completely reliable.